MNPR
Price
$77.19
Change
+$1.24 (+1.63%)
Updated
Dec 3 closing price
Capitalization
512.69M
Intraday BUY SELL Signals
QNCX
Price
$3.50
Change
+$0.12 (+3.55%)
Updated
Dec 3, 04:59 PM (EDT)
Capitalization
177.62M
89 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MNPR vs QNCX

Header iconMNPR vs QNCX Comparison
Open Charts MNPR vs QNCXBanner chart's image
Monopar Therapeutics
Price$77.19
Change+$1.24 (+1.63%)
Volume$189.27K
Capitalization512.69M
Quince Therapeutics
Price$3.50
Change+$0.12 (+3.55%)
Volume$35.03K
Capitalization177.62M
MNPR vs QNCX Comparison Chart in %
MNPR
Daily Signal:
Gain/Loss:
QNCX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
MNPR vs. QNCX commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MNPR is a StrongBuy and QNCX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (MNPR: $75.86 vs. QNCX: $3.39)
Brand notoriety: MNPR and QNCX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MNPR: 91% vs. QNCX: 124%
Market capitalization -- MNPR: $512.69M vs. QNCX: $196M
MNPR [@Biotechnology] is valued at $512.69M. QNCX’s [@Biotechnology] market capitalization is $196M. The market cap for tickers in the [@Biotechnology] industry ranges from $117.5B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MNPR’s FA Score shows that 1 FA rating(s) are green whileQNCX’s FA Score has 0 green FA rating(s).

  • MNPR’s FA Score: 1 green, 4 red.
  • QNCX’s FA Score: 0 green, 5 red.
According to our system of comparison, MNPR is a better buy in the long-term than QNCX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MNPR’s TA Score shows that 4 TA indicator(s) are bullish while QNCX’s TA Score has 5 bullish TA indicator(s).

  • MNPR’s TA Score: 4 bullish, 4 bearish.
  • QNCX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both MNPR and QNCX are a good buy in the short-term.

Price Growth

MNPR (@Biotechnology) experienced а -14.25% price change this week, while QNCX (@Biotechnology) price change was +26.97% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +1.23%, and the average quarterly price growth was +54.93%.

Reported Earning Dates

QNCX is expected to report earnings on Mar 03, 2026.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MNPR($513M) has a higher market cap than QNCX($178M). MNPR YTD gains are higher at: 244.818 vs. QNCX (81.283). MNPR has higher annual earnings (EBITDA): -19.11M vs. QNCX (-41.32M). MNPR has more cash in the bank: 53.3M vs. QNCX (34.7M). MNPR has less debt than QNCX: MNPR (80.4K) vs QNCX (17.5M). MNPR (0) and QNCX (0) have equivalent revenues.
MNPRQNCXMNPR / QNCX
Capitalization513M178M288%
EBITDA-19.11M-41.32M46%
Gain YTD244.81881.283301%
P/E RatioN/AN/A-
Revenue00-
Total Cash53.3M34.7M154%
Total Debt80.4K17.5M0%
FUNDAMENTALS RATINGS
MNPR vs QNCX: Fundamental Ratings
MNPR
QNCX
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
93
Overvalued
PROFIT vs RISK RATING
1..100
38100
SMR RATING
1..100
9799
PRICE GROWTH RATING
1..100
3434
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MNPR's Valuation (30) in the null industry is somewhat better than the same rating for QNCX (93) in the Biotechnology industry. This means that MNPR’s stock grew somewhat faster than QNCX’s over the last 12 months.

MNPR's Profit vs Risk Rating (38) in the null industry is somewhat better than the same rating for QNCX (100) in the Biotechnology industry. This means that MNPR’s stock grew somewhat faster than QNCX’s over the last 12 months.

MNPR's SMR Rating (97) in the null industry is in the same range as QNCX (99) in the Biotechnology industry. This means that MNPR’s stock grew similarly to QNCX’s over the last 12 months.

MNPR's Price Growth Rating (34) in the null industry is in the same range as QNCX (34) in the Biotechnology industry. This means that MNPR’s stock grew similarly to QNCX’s over the last 12 months.

MNPR's P/E Growth Rating (100) in the null industry is in the same range as QNCX (100) in the Biotechnology industry. This means that MNPR’s stock grew similarly to QNCX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MNPRQNCX
RSI
ODDS (%)
N/A
Bearish Trend 7 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 7 days ago
82%
Bearish Trend 7 days ago
84%
Momentum
ODDS (%)
Bearish Trend 7 days ago
85%
Bullish Trend 7 days ago
90%
MACD
ODDS (%)
Bullish Trend 7 days ago
75%
Bullish Trend 7 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 7 days ago
82%
Bullish Trend 7 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 7 days ago
81%
Bullish Trend 7 days ago
87%
Advances
ODDS (%)
Bullish Trend 11 days ago
83%
Bullish Trend 7 days ago
85%
Declines
ODDS (%)
Bearish Trend 7 days ago
88%
Bearish Trend 22 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 7 days ago
80%
Bearish Trend 7 days ago
81%
Aroon
ODDS (%)
Bullish Trend 7 days ago
74%
Bearish Trend 7 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
MNPR
Daily Signal:
Gain/Loss:
QNCX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MGINX11.32N/A
N/A
DWS Global Macro Inst
LHCVX23.45N/A
N/A
Lord Abbett Health Care R6
JHLVX57.50N/A
N/A
JHancock Fundamental Large Cap Core C
CMVIX29.80N/A
N/A
BlackRock Advantage Large Cap Gr Instl
RSCRX27.35N/A
N/A
Russell Inv US Small Cap Equity R6

MNPR and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNPR has been loosely correlated with QNCX. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if MNPR jumps, then QNCX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNPR
1D Price
Change %
MNPR100%
-8.67%
QNCX - MNPR
35%
Loosely correlated
+6.94%
OCGN - MNPR
31%
Poorly correlated
-1.69%
IDYA - MNPR
31%
Poorly correlated
-1.75%
XNCR - MNPR
30%
Poorly correlated
-3.15%
KURA - MNPR
30%
Poorly correlated
-2.53%
More

QNCX and

Correlation & Price change

A.I.dvisor indicates that over the last year, QNCX has been loosely correlated with MNPR. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if QNCX jumps, then MNPR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QNCX
1D Price
Change %
QNCX100%
+6.94%
MNPR - QNCX
35%
Loosely correlated
-8.67%
ADCT - QNCX
31%
Poorly correlated
+8.61%
CLNN - QNCX
29%
Poorly correlated
-2.09%
KOD - QNCX
28%
Poorly correlated
+0.32%
MDXG - QNCX
27%
Poorly correlated
+0.67%
More